Stephen Ewald - Medpace Holdings General Counsel, Corporate Secretary
| MEDP Stock | USD 337.82 0.07 0.02% |
Executive
Mr. Stephen P. Ewald, J.D. is a General Counsel, Corporationrationrate Secretary of the Company. Stephen P. Ewald joined Medpace as General Counsel and Corporationrationrate Secretary in June 2012. Mr. Ewald has also led the Human Resources department and other administrative functions since the third quarter of 2017. Prior to joining Medpace, Mr. Ewald served as the Managing Director and Chief Legal Officer of Brevet Capital Management from May 2011 to June 2012. From May 2009 to May 2011, he was a Managing Director and Assistant General Counsel for Cantor Fitzgerald SecuritiesCantor Fitzgerald Co. Mr. Ewald was employed with Bank of America from 1999 to 2009, serving in various roles within the legal department and the Global Markets Group, including Managing Director and Chief Operating Officer of the Principal Capital Group, a proprietary investing group within Bank of America Securities. Mr. Ewald has served as director for several private companies, including as a director of Mercy Health Foundation Board Cincinnati since 2015, as a director of LIB Therapeutics, LLC since 2015 and as a director of CinRx Pharma, LLC since 2015 since 2012.
| Age | 55 |
| Tenure | 12 years |
| Address | 5375 Medpace Way, Cincinnati, OH, United States, 45227 |
| Phone | 513 579 9911 |
| Web | https://www.medpace.com |
Medpace Holdings Management Efficiency
The company has return on total asset (ROA) of 0.1431 % which means that it generated a profit of $0.1431 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.5408 %, meaning that it created $0.5408 on every $100 dollars invested by stockholders. Medpace Holdings' management efficiency ratios could be used to measure how well Medpace Holdings manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/26/2024, Return On Tangible Assets is likely to grow to 0.31. Also, Return On Capital Employed is likely to grow to 0.48. At this time, Medpace Holdings' Total Current Liabilities is relatively stable compared to the past year. As of 11/26/2024, Non Current Liabilities Total is likely to grow to about 182.2 M, while Liabilities And Stockholders Equity is likely to drop slightly above 1.3 B.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sarah Demey | Neogen | N/A | |
| Anita Graham | Laboratory of | 53 | |
| Peter Schueler | ICON PLC | N/A | |
| Thomas Neidert | Qiagen NV | N/A | |
| Nigel ACA | ICON PLC | 50 | |
| Jonathan Curtain | ICON PLC | 48 | |
| Ken Grady | IDEXX Laboratories | N/A | |
| Amy Cianciaruso | Charles River Laboratories | N/A | |
| Miriame Victor | Revvity | 42 | |
| Christian Magloth | Mettler Toledo International | 58 | |
| Mary Finnegan | Mettler Toledo International | N/A | |
| Antonio Santos | Qiagen NV | N/A | |
| Todd Spencer | Charles River Laboratories | N/A | |
| Stephen Willoughby | Revvity | N/A | |
| Joseph JD | Charles River Laboratories | 50 | |
| Akinbolade Oyegunwa | Laboratory of | N/A | |
| Gerhard Keller | Mettler Toledo International | 56 | |
| Arvind SundarRajan | Revvity | N/A | |
| Amy Rocklin | Neogen | 52 | |
| Stephany Foster | Qiagen NV | 45 | |
| Kristen Garvey | Waters | N/A | |
Management Performance
| Return On Equity | 0.54 | ||||
| Return On Asset | 0.14 |
Medpace Holdings Leadership Team
Elected by the shareholders, the Medpace Holdings' board of directors comprises two types of representatives: Medpace Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medpace. The board's role is to monitor Medpace Holdings' management team and ensure that shareholders' interests are well served. Medpace Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medpace Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Susan Burwig, Senior Vice President - Operations | ||
| Kevin Brady, CFO Treasurer | ||
| Brandon Ebken, Chief Officer | ||
| August MD, Chairman CEO | ||
| Stephen JD, General Officer | ||
| Stephen Ewald, General Counsel, Corporate Secretary | ||
| Todd Meyers, Vice Marketing | ||
| Reinilde MD, Chief Department | ||
| Weimin MS, VP Biometrics | ||
| Daniel OLeary, VP Department | ||
| John MBA, Senior Unit | ||
| MA BSN, Executive Operations | ||
| CPA BBA, President | ||
| Lauren Morris, Associate Relations |
Medpace Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medpace Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.54 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 9.97 B | ||||
| Shares Outstanding | 31.08 M | ||||
| Shares Owned By Insiders | 17.70 % | ||||
| Shares Owned By Institutions | 85.99 % | ||||
| Number Of Shares Shorted | 1.1 M | ||||
| Price To Earning | 49.07 X |
Pair Trading with Medpace Holdings
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medpace Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medpace Holdings will appreciate offsetting losses from the drop in the long position's value.Moving against Medpace Stock
| 0.41 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.35 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.34 | FLGC | Flora Growth Corp | PairCorr |
| 0.32 | VRDN | Viridian Therapeutics | PairCorr |
| 0.32 | AQB | AquaBounty Technologies | PairCorr |
The ability to find closely correlated positions to Medpace Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medpace Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medpace Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medpace Holdings to buy it.
The correlation of Medpace Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medpace Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medpace Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medpace Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Medpace Stock Analysis
When running Medpace Holdings' price analysis, check to measure Medpace Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medpace Holdings is operating at the current time. Most of Medpace Holdings' value examination focuses on studying past and present price action to predict the probability of Medpace Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medpace Holdings' price. Additionally, you may evaluate how the addition of Medpace Holdings to your portfolios can decrease your overall portfolio volatility.